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ABSTRACT
Objective To provide guidance to researchers, funders, 
regulators and study delivery teams to ensure that 
research on COVID-19 is inclusive, particularly of groups 
disproportionately affected by COVID-19 and who may 
have been historically under- served by research.
Summary of key points Groups who are 
disproportionately affected by COVID-19 include (but are 
not limited to) older people, people with multiple long- 
term conditions, people with disabilities, people from 
Black, Asian and Ethnic minority groups, people living with 
obesity, people who are socioeconomically deprived and 
people living in care homes. All these groups are under- 
served by clinical research, and there is an urgent need 
to rectify this if COVID-19 research is to deliver relevant 
evidence for these groups who are most in need. We 
provide a framework and checklists for addressing key 
issues when designing and delivering inclusive COVID-19 
research, based on the National Institute for Health 
Research INnovations in CLinical trial design and delivery 
for the UnDEr- served project roadmap. Strong community 
engagement, codevelopment and prioritisation of research 
questions and interventions are essential. Under- served 
groups should be represented on funding panels and 
ethics committees, who should insist on the removal 
of barriers to participation. Exclusion criteria should be 
kept to a minimum; intervention delivery and outcome 
measurement should be simple, flexible and tailored to 
the needs of different groups, and local advice on the best 
way to reach and engage with under- served communities 
should be taken by study delivery teams. Data on 
characteristics that allow identification of under- served 
groups must be collected, analyses should include these 
data to enable subgroup comparisons and results should 
be shared with under- served groups at an early stage.
Conclusion Inclusive COVID-19 research is a necessity, 
not a luxury, if research is to benefit all the communities it 
seeks to serve. It requires close engagement with under- 
served groups and attention to aspects of study topic, 
design, delivery, analysis and dissemination across the 
research life cycle.
INTRODUCTION
COVID-19 is challenging health systems glob-
ally and has triggered an unprecedented 
research response.1 Across the world, teams 
are designing and delivering studies encom-
passing a range of COVID-19 research 
including epidemiology, disease surveil-
lance, disease consequences, early and late 
phase clinical trials. Early evidence suggests 
that some segments of the population are at 
high risk either of contracting COVID-19 or 
of more severe consequences of COVID-19 
including hospitalisation and death.2 3 Some 
of these groups have not been well reached 
by traditional research design and delivery 
mechanisms,4 and there is growing concern 
that some of the groups most vulnerable to the 
impact of COVID-19 are under- represented 
in research studies.5
This guidance is designed to facilitate best 
practice in the design, funding, approval, regu-
lation and delivery of research on COVID-19 
and is a product of the ongoing National 
Institute for Health Research (NIHR) INno-
vations in CLinical trial design and delivery 
for the UnDEr- served (INCLUDE) project 
which seeks to improve research for under- 
served groups; the guidance has been made 
available by the NIHR website.6
What is an under-served group?
There is no single definition of an under- 
served group in research; the definition is 
Strengths and limitations of this study
 ► We provide detailed guidance across the research 
life cycle—a whole- systems approach to improve 
inclusion in COVID-19 research.
 ► We base the guidance on the robustly developed 
INnovations in CLinical trial design and delivery for 
the UnDEr- served roadmap for improving inclusion 
in research.
 ► The novelty of COVID-19 research precludes our 
recommendations being based on evidence directly 
derived from studies with people with COVID-19.
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context- dependent and will vary depending on the popu-
lation, disease and intervention being studied.7 However, 
if a group is enrolled in a study at lower rates than one sees 
in the population affected by the disease, this is evidence 
that the group is likely to be under- served. Reasons for a 
group being under- served may include protocol design 
exclusions, an intervention that is unsuitable for that 
group or because research delivery does not enable them 
to participate in practice.
Who is at risk of contracting COVID-19?
Our knowledge of who is more or less likely to be infected 
with COVID-19 (as opposed to suffering severe conse-
quences of infection) is limited at present. However, 
individuals with a high degree of contact with those who 
are infected, including healthcare workers, retail staff, 
transport staff and other key workers with face- to- face 
roles, are likely to be at high risk. Other groups in which 
risk appears elevated are patients who spend prolonged 
periods of time in close proximity to other patients (eg, 
patients attending hospital- based haemodialysis8) and 
those in care homes9; emerging evidence suggests that 
once COVID-19 starts to affect a care home, it can spread 
very rapidly through the care home population of both 
residents and staff.
Who is at risk of severe consequences of COVID-19?
Emerging data suggest that several groups are at a 
higher risk of death or critical care unit admission from 
COVID-19 infection.2 3 10 These groups include, but are 
not limited to, older people (particularly those aged 70 
and over); men; people living with obesity; people with 
disabilities, people living with multiple long- term condi-
tions; care home residents and others living with frailty; 
Black, Asian and minority ethnic (BAME) groups; and 
people with immunosuppression due to medication, 
systemic illness or malnutrition.
What groups may be under-served by healthcare and research 
systems with respect to COVID-19?
This is also likely to be context- specific, but examples 
include the following.
 ► Older people and others who are self- isolating (who 
may not be able to access healthcare easily) on govern-
ment advice.
 ► Those who may not be prioritised for hospital admis-
sion or critical care unit admission due to perceived 
limited life expectancy or a low chance of benefitting 
from such interventions.
 ► Those who lack digital literacy or access to digital 
technologies.
 ► People with cognitive problems including dementia, 
especially those living alone, who may not be able to 
understand and/or adhere to the symptom reporting 
and testing needed for diagnosis.
 ► People with disabilities, who may not be able to access 
information or testing facilities and may struggle to 
access healthcare and care support during periods of 
lockdown.11
 ► Socioeconomically deprived groups, who are likely to 
have less resilience to the economic shocks precipi-
tated by the COVID-19 pandemic response.
 ► People without a car or who live in rural areas (who 
may find it difficult to access testing facilities that 
require attendees to come in a car).
In addition, thought needs to be given to the fear that 
many of the population currently have of leaving their 
immediate environment, entering a hospital or other 
healthcare facility. This may disproportionately affect 
certain segments of the population (eg, those with 
anxiety disorders or who perceive themselves to be espe-
cially vulnerable).
How can under-served groups be more successfully included 
in COVID-19 research?
The INCLUDE project contains a roadmap outlining the 
potential points of intervention to improve the inclusion 
Figure 1 The INCLUDE roadmap (reproduced from National Institute for Health Research [6] under a creative commons 
attribution 4.0 international license).
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of under- served groups (figure 1) and a structure that 
may be helpful in guiding teams considering how to 
focus their efforts. Ensuring that effective training for 
researchers, funders, delivery teams and regulators is key, 
as is ensuring that regulation is proportionate and does 
not place barriers in the way of including under- served 
groups. Identifying members of under- served groups and 
using their knowledge is critical to successful delivery of 
research, as is building on existing resources that have 
been created to facilitate research for specific under- 
served groups such as older people12 or people from 
BAME communities.13
Recommendations from the include project for COVID-19 
research
Below, we set out a series of recommendations across the 
research life cycle for how under- served groups can be 
included more successfully in COVID-19 research.
Research priority setting
 ► Representatives from under- served groups should be 
consulted at the earliest possible time to agree a set of 
national research priorities for COVID-19 research. A 
rapid James Lind Alliance project (a priority- setting 
process co- produced by researchers, patients and a 
range of other stakeholders) would be one possible 
way to achieve this, but opportunities also exist to 
ensure representation on COVID-19 funding commit-
tees and prioritisation committees.
Strategic priorities for funding bodies
 ► Strategic priorities for research funding bodies (eg, 
government funders and charities) should reflect 
the views of under- served groups from any national 
or international research priority exercise, as well as 
reflecting current scientific paradigms and national 
health and social care system imperatives.
 ► Patient and public representation should be in place 
on all COVID-19- related funding and prioritisa-
tion panels, and this patient and public representa-
tion should encompass representatives from groups 
who are at risk of being under- served by COVID-19 
research.
Research investigator questions
 ► Specific research questions to be answered should be 
codeveloped by research teams, funders, government 
and patient and public representatives including 
people from under- served groups.
Initial design and funding
 ► Inclusion criteria for research studies should be kept 
to the minimum necessary to ensure patient safety 
and criteria likely to exclude broad sectors of popula-
tions should be avoided. In particular, we recommend 
that studies do not overtly or inadvertently exclude 
participants on the basis of age, sex, ethnicity, geog-
raphy, socioeconomic status, multimorbidity, disa-
bility, cognitive impairment, body mass index or place 
of residence unless studies specifically aim to generate 
data for groups that have to date been under- served 
by COVID-19 research.
 ► Interventions should be designed and selected to be 
usable by a wide range of participants, including those 
from under- served groups. If this is not possible, then 
serious consideration should be given to abandoning 
the intervention on the grounds that it will not be 
broadly applicable in practice. Exceptions to this are 
interventions designed to target a specific biological 
pathway identified by disease severity or other disease 
characteristics (ie, stratified or precision medicine 
approaches), or interventions designed specifically to 
target under- served groups where current approaches 
are not sufficiently effective.
 ► Outcomes should be selected to be relevant to a broad 
range of participants; outcomes should be simple and 
should place minimal burden on both participants 
and research teams. Outcomes should be deliver-
able under pandemic conditions (eg, when wearing 
full personal protective equipment (PPE) in over-
loaded hospitals). Outcomes that can be collected 
from routinely collected clinical data or participant- 
reported outcomes that have the flexibility to be 
collected by telephone, by video link, by remote 
devices (eg, accelerometers or other Bluetooth- 
enabled devices14) or by web- based/SMS interfaces 
should be preferred, ensuring that such platforms can 
be used by participants with a range of sensory and 
motor disabilities.
 ► When outcomes must be collected face to face, these 
should be able to be collected in a range of different 
environments including the participant’s own home, 
not just in hospital wards or clinics. Outcomes should, 
where possible, be able to be assessed by a range of 
staff with no or minimal training to ensure that studies 
are resilient against staff illness or redeployment 
in future pandemic waves. Research teams should 
build the costs of hardware, software, accommoda-
tions for people with disability and adequate time to 
support these outcome collection methods into their 
proposals.
 ► Researchers should design study protocols to allow 
recruitment through as wide a range of routes as 
possible. Without good scientific reason, recruit-
ment should not be limited to hospitals, primary care 
practices or care institutions, but should be enabled 
through all of these routes and others including 
through community social hubs and organisations, via 
adverts, web- based signup, verbally over the telephone, 
in response to SMS and traditional mail, and other 
routes appropriate to reach particular under- served 
groups. The emergence of new community networks 
to support isolated and vulnerable people during the 
pandemic provides new opportunities for contacting 
and engaging under- served groups in research. Key 
issues to consider when designing COVID-19 studies 
are given in box 1.
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 ► Funders can apply the checklist given later in this 
document (see box 2) to assess whether research 
proposals have been developed in conjunction with 
under- served groups and that proposals are designed 
and will be delivered in a way likely to be able to 
recruit under- served groups successfully in COVID-19 
research.
 ► Funders should ensure that additional funds (above 
and beyond the amount of money traditionally viewed 
as adequate to support recruitment and retention) are 
available to research teams to support the successful 
recruitment of under- served groups. This may require 
funds for home visiting, transportation (in many 
cases by car or taxi, not public transport), PPE, more 
screening per participant recruited, longer study 
visits, provision of translators or translated materials.
Final study design
 ► Research Ethics Committees should pay particular 
attention to inclusion and exclusion criteria, routes of 
recruitment, information materials, consent processes 
(including the needs of those without capacity) and 
whether under- served groups have been engaged in 
study design. Where study designs seem likely to fail to 
include sufficient people from under- served groups, 
ethics committees should robustly call attention to 
this and ask research teams to modify their proposals 
accordingly even if doing so leads to short delays in 
approval of projects. Key issues to consider are listed 
in box 2.
 ► Sponsor organisations should apply similar scrutiny 
to research proposals at the design stage and insist 
on changes where the design makes the exclusion of 
under- served groups likely.
 ► Sponsor organisations and Research Ethics Commit-
tees should both welcome and encourage novel 
and efficient methods of approaching, consenting, 
recruiting and retaining participants in research 
studies. Many proposals will be very different from 
those that such organisations are used to seeing, but 
this should be viewed as an opportunity, not a reason 
to fall back on traditional (and often ineffective) 
methods of study conduct.
Study delivery
 ► Local research delivery teams should seek local advice 
on how to reach and engage with under- served groups 
in their areas. In many cases, this will entail getting advice 
from members of specific ethnic communities, or those 
with lived experience of particular population sectors (eg, 
those living in care homes, homeless people). In selected 
cases, this may extend to using members of under- served 
communities to deliver research. Key issues to consider 
are listed in box 3.
Box 2 A checklist to guide funders and reviewers in 
assessing inclusiveness of COVID-19 research
 ► Does the topic of the study reflect the priorities elicited by consulta-
tion with under- served groups?
 ► Have representatives from under- served groups been engaged in 
the design of the study, and in what way?
 ► Does the target population for the study (as defined by the inclusion 
and exclusion criteria) reflect those who are at risk of contracting 
COVID-19 or who are at increased risk of the adverse consequences 
of COVID-19?
 ► Have the investigators taken steps to ensure that these potentially 
under- served groups will be included in the study with appropriate 
mitigation of any risks?
 ► Are there unnecessary or unjustifiable exclusion criteria (eg, old 
age, sex, ethnicity, obesity, cognitive impairment, multimorbidity) or 
research methods that will act as barriers to inclusion of under- 
served groups at high risk of COVID-19 infection and its adverse 
consequences?
 ► Is the intervention designed and delivered in a way that is accept-
able and feasible to a broad range of people most at risk from 
COVID-19 infection?
 ► Are the study outcomes easy to measure, and can they be measured 
in a range of different environments? Will they still be able to be 
measured during the peak of a pandemic wave or during population 
lockdown?
 ► Does the study target a specific under- served group? If so, is ad-
equate justification for this given, and is the strategy proposed to 
target the group likely to succeed?
Box 1 A checklist to guide researchers in designing 
inclusive COVID-19 research
 ► Have I engaged with representatives of under- served groups in de-
signing my study question and protocol?
 ► Have I avoided inclusion/exclusion criteria likely to lead to exclusion 
of under- served groups? (eg, age limits, excluding multimorbidities, 
body mass index limits)
 ► Is my study intervention suitable for, and acceptable to, under- 
served groups? (eg, avoiding gelatine capsules on medication)
 ► Are my outcomes validated and relevant to a broad range of patients 
in the populations that my research seeks to serve? (eg, cognition 
assessment tools in translated versions)
 ► Have I avoided study burden that is likely to make it more difficult for 
some groups to participate? (eg, frequent study visits)
 ► Have I provided a range of recruitment pathways that give flexibility 
in how participants are sought and contacted? (eg, not confining 
recruitment to drive- in testing centres, allowing recruitment from 
care homes)
 ► Have I provided study information in a format that is accessible to 
under- served groups? (eg, translations of study information, simpli-
fied study information, information written with a reading age of 9 or 
below, written in large font size, screen reader compatible)
 ► Have I enabled consent to be obtained in a way that is flexible and 
tailored to the needs of different groups? (eg, EConsent for those 
isolating, assent or supported decision making from relatives for 
those with cognitive impairment). Have I involved carers and assen-
tees in the design of the assent process for studies where consent 
cannot be obtained from the participant?
 ► Will my study still be deliverable in the event of a second pandemic 
wave, with a possible increase in lockdown restrictions and study 
staff redeployment?
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 ► Training for research delivery staff (local investi-
gators, research nurses and other research team 
members) should be delivered to raise awareness of 
the need to recruit inclusively, to highlight particular 
under- served groups and to provide the generic skills 
required to engage with specific under- served groups.
 ► Local research teams should configure themselves to 
be able to recruit in environments other than standard 
inpatient and outpatient secondary care departments. 
This should include conducting study procedures in 
participants’ own homes, care homes, conducting study 
procedures remotely (eg, via telephone and video links) 
and taking care to accommodate the needs of those 
with a range of disabilities. Linking with neighbouring 
healthcare research organisations will enable cross- cover 
of research staff in the event of staff sickness or of one 
organisation becoming overloaded by clinical work in 
future pandemic waves.
 ► For trials of medicinal products, dispensing arrangements 
for oral medications should be put in place to enable the 
delivery of medications directly to participants’ homes or 
local pharmacy rather than needing to collect medica-
tion from a research facility. This approach will help to 
build resilience against future restrictions on movement 
or closure of workplaces.
 ► Local research support agencies (such as the UK NIHR 
local Clinical Research Networks and hospital Trusts) 
should provide local research teams with the equipment 
and resources that they need to deliver research in non- 
traditional settings. This may include transportation, 
contracts and working practice procedures enabling 
work in participants’ homes, provision of COVID-19 
testing and PPE in line with national guidance, IT hard-
ware and software to enable video links, EConsent and 
electronic case record form use while roaming, transla-
tion services and sufficient time to conduct study visits in 
non- traditional settings.
 ► Local research support agencies should put in place 
systems to monitor local recruitment of under- served 
groups to each study. Combining these local data across 
studies will enable study teams to adapt their recruit-
ment strategies at an early point, for instance, switching 
place of recruitment, oversampling particular under- 
served groups or changing how study teams approach 
participants.
Study closure and analysis
 ► Investigators and sponsors should develop plans for how 
pauses or discontinuation of study activity due to future 
pandemic waves will be managed (ideally to at least 
enable the study follow- up to continue), and how these 
plans will be communicated to participants.
 ► Study reports and analysis plans should report the propor-
tion of relevant under- served groups and compare these 
proportions to those found in the general population 
with COVID-19 illness.
 ► Study analysis plans should include adequately 
powered prespecified subgroup analyses for key 
under- served groups, both to explore differences 
within studies and to enable later pooling of results 
from different under- served groups.
Impact, dissemination and engagement
 ► All studies should devise a comprehensive dissem-
ination and engagement plan, and representatives 
from under- served groups should be part of the team 
drawing up these plans.
 ► Specific engagement plans for different under- served 
groups should be drawn up to enable appropriate 
tailoring of messages to different groups, in a way that 
best encourages feedback, debate and engagement 
within different groups.
CONCLUSION
At a time when research on COVID-19 is being designed and 
delivered at an extraordinary speed, it may seem that the 
urgency of the situation obviates the need to fully engage 
under- served groups in the design and delivery of COVID-19 
research. We argue however that doing so is not a luxury but 
a necessity and failure to engage represents an enormous 
wasted opportunity.15 It will hamper scientific progress and 
potentially lead to the deployment of ineffective or harmful 
diagnostics and therapeutics to large sections of the popu-
lation. This in turn will lead to worse health outcomes for 
under- served groups, and healthcare resources being wasted. 
Fully engaging under- served groups and enabling their inclu-
sion in COVID-19 research is the only way that we will be able 
to understand the health impacts of COVID-19 in these most 
vulnerable groups and thus mitigate the impact of COVID-19 
on health and society in an equitable way.
Box 3 A checklist to guide research delivery teams in 
delivering inclusive COVID-19 research
 ► Have we engaged with local representatives from under- served 
groups to understand how best to approach, recruit and retain par-
ticipants to this study locally?
 ► Are our staff trained to approach and recruit people from under- served 
groups? (eg, those living in care homes). If not, what training is required 
(eg, age inclusion training, disability inclusion training) and how will we 
deliver this?
 ► Do our staff have the correct equipment to deliver the study to under- 
served groups (eg, portable testing and blood taking kit, car transport 
and PPE to conduce home visits, contracts and lone working policies to 
support home working, video and phone consulting systems to enable 
remote follow- up, accommodations to support the inclusion of people 
with disabilities)?
 ► Do we have staff with particular skills or background who would be well 
suited to engage with under- served groups (eg, speak the same lan-
guage, live in the same area, experience working in a particular health-
care sector)?
 ► Do we have processes in place locally to monitor whether we are 
reaching people from under- served groups—and if not, why not?
 ► If recruiting people from under- served groups is taking more time 
or resources, is the extra time and resource being made available, 
either from the funder or from local resources?
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